Safety information changes as regulators review evidence from medicine use outside clinical trials.
What changed?
The MHRA strengthened warnings about acute pancreatitis for GLP-1 and dual GLP-1/GIP receptor agonists. The update highlights rare reports of severe, necrotising and fatal cases.
What should readers recognise?
The regulator advises urgent medical attention for severe, persistent abdominal pain, which may spread to the back and occur with nausea or vomiting. The MHRA advises that treatment must not be restarted if pancreatitis is confirmed.
What do adverse-event reports mean?
Spontaneous reports help identify and investigate possible safety signals. They cannot, by themselves, show how often a side effect occurs or prove that a medicine caused each reported event.
Where to find the complete advice
Read the original MHRA update and the patient information leaflet for the particular medicine. Suspected side effects can be reported through the MHRA Yellow Card scheme. This summary is not a diagnosis or a complete list of risks.
Read the source
MHRA Drug Safety Update · 29 January 2026
Based on the official regulator announcement. This report does not replace the complete product information.
This publication provides general information, not personalised medical advice. Discuss treatment decisions with an appropriately qualified clinician.